Table 2.
Patients and tumor characteristics of those with positive vs negative sentinel lymph nodes
| Characteristic | Positive SLN (n = 19) n (%)a |
Negative SLN (n = 14) n (%)a |
P value |
|---|---|---|---|
| Age at diagnosis | 0.21 | ||
| Mean (SD) | 13.16 (3.95) | 11.71 (4.1) | |
| Median (range) | 14 (2, 21) | 11.5 (4, 18) | |
| Age at diagnosis | > 0.99 | ||
| < 10 years | 3 (16%) | 3 (21%) | |
| ≥ 10 years | 16 (84%) | 11 (79%) | |
| Sex | 0.45 | ||
| Female | 7 (37%) | 7 (50%) | |
| Male | 12 (63%) | 7 (50%) | |
| Primary tumor location | 0.062 | ||
| Extremity | 3 (16%) | 6 (43%) | |
| Head or neck | 4 (21%) | 5 (36%) | |
| Trunk | 12 (63%) | 3 (21%) | |
| Depth (mm) | 0.25 | ||
| Mean (SD) | 3.75 (2.43) | 3.1 (2.72) | |
| Median (range) | 3.3 (1.3, 9.4) | 2.02 (0.42–9.20) | |
| Tumor depth | 0.28 | ||
| T1 | – | 3 (21%) | |
| T2 (1.01–2.00 mm) | 7 (37%) | 4 (29%) | |
| T3 (2.01–4.00 mm) | 6 (32%) | 3 (21%) | |
| T4 (> 4.00 mm) | 6 (32%) | 4 (29%) | |
| N/A | |||
| Ulceration | 0.17 | ||
| Yes | 10 (53%) | 4 (29%) | |
| No | 9 (47%) | 10 (71%) | |
| Mitosis | 0.56 | ||
| Absence | 1 (5%) | 2 (14%) | |
| Presence | 18 (95%) | 12 (86%) | |
| Mitotic counts | 0.37 | ||
| Mean | 6.79 (6.38) | 5.87 (6.84) | |
| Median | 5 (0, 26) | 3 (0, 21) | |
| Margin statusb | 0.016 | ||
| 1–5 mm | 7 (37%) | 2 (14%) | |
| 5–10 mm | 2 (11%) | 4 (29%) | |
| > 10 mm | 4 (21%) | 8 (57%) | |
| Free | 6 (32%) | – | |
| Adjuvant treatmentc | < 0.001 | ||
| Yes | 17 (89%) | 2 (14%) | |
| No | 2 (11%) | 12 (86%) | |
| Median number (range) of SLN identified per patient | 3 (1,7) | 2 (1,13) | 0.37 |
CM conventional melanoma, SD standard deviation, mm millimeter, SLN sentinel lymph node
aValues indicate the number of patients (%), unless otherwise indicated
bMargin status indicates the size of the resection margin
cAdjuvant treatment included interferon alpha or immunotherapy